Production (Stage)
Candel Therapeutics, Inc.
CADL
$5.08
-$0.08-1.55%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -23.29% | -25.38% | 101.48% | 51.72% | 63.31% |
| Gross Profit | 23.29% | 25.38% | -101.88% | -52.18% | -64.07% |
| SG&A Expenses | 4.91% | -0.06% | -1.12% | -6.66% | -6.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.41% | -14.13% | -2.89% | -2.74% | 2.28% |
| Operating Income | 9.41% | 14.13% | 2.81% | 2.58% | -2.55% |
| Income Before Tax | -5.92% | -45.44% | -63.49% | -55.34% | -39.87% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.92% | -45.44% | -63.49% | -55.34% | -39.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.92% | -45.44% | -63.49% | -55.34% | -39.87% |
| EBIT | 9.41% | 14.13% | 2.81% | 2.58% | -2.55% |
| EBITDA | 9.68% | 14.58% | 3.06% | 2.93% | -2.21% |
| EPS Basic | -2.93% | -33.80% | -57.70% | -52.76% | -39.34% |
| Normalized Basic EPS | -2.37% | -33.56% | -56.48% | -51.56% | -37.91% |
| EPS Diluted | -4.19% | -33.80% | -57.70% | -52.76% | -39.34% |
| Normalized Diluted EPS | -3.27% | -33.56% | -56.48% | -51.56% | -37.91% |
| Average Basic Shares Outstanding | 27.51% | 9.43% | 3.81% | 1.16% | 0.43% |
| Average Diluted Shares Outstanding | 31.20% | 9.43% | 3.81% | 1.16% | 0.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |